
IndraLab
Statements
Antagonist inhibits NLRP3. 3 / 3
|
1
1
1
reach
"Among the latter, anakinra is the recombinant form of the IL-1 receptor antagonist, known to inhibit NLRP3 via blockade of the IL-1 receptor I. Anakinra is currently used to treat a wide range of diseases that goes beyond its approved indications for rheumatoid arthritis and cryopyrin-associated periodic syndromes, to encompass cancer and chronic inflammatory diseases 9 ."